ANDRX, TAKEDA FILE NDA FOR DIABETES DRUG

A A

Andrx and Takeda Pharmaceuticals have filed a new drug application (NDA) for a combination product to treat Type 2 diabetes.

The product would combine Takeda's Actos (pioglitazone HCl) and Andrx's Fortamet (metformin HCl) extended-release tablets, each of which is administered once daily for the treatment of Type 2 diabetes. The drugmakers announced an agreement in January 2004 to develop and market the combination product.